Elizabeth Nichols1, Susan B Kesmodel2, Emily Bellavance2, Cynthia Drogula2, Katherine Tkaczuk3, Randi J Cohen4, Wendla Citron4, Michelle Morgan4, Paul Staats5, Steven Feigenberg4, William F Regine4. 1. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: Enichols1@umm.edu. 2. Department of Surgical Oncology, University of Maryland School of Medicine, Baltimore, Maryland. 3. Department of Medical Oncology, University of Maryland School of Medicine, Baltimore, Maryland. 4. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland. 5. Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.
Abstract
PURPOSE: To assess the feasibility of utilizing 3-dimensional conformal accelerated partial-breast irradiation (APBI) in the preoperative setting followed by standard breast-conserving therapy. PATIENTS AND METHODS: This was a prospective trial testing the feasibility of preoperative APBI followed by lumpectomy for patients with early-stage invasive ductal breast cancer. Eligible patients had T1-T2 (<3 cm), N0 tumors. Patients received 38.5 Gy in 3.85-Gy fractions delivered twice daily. Surgery was performed >21 days after radiation therapy. Adjuvant therapy was given as per standard of care. RESULTS: Twenty-seven patients completed treatment. With a median follow-up of 3.6 years (range, 0.5-5 years), there have been no local or regional failures. A complete pathologic response according to hematoxylin and eosin stains was seen in 4 patients (15%). There were 4 grade 3 seromas. Patient-reported cosmetic outcome was rated as good to excellent in 79% of patients after treatment. CONCLUSIONS: Preoperative 3-dimensional conformal radiation therapy-APBI is feasible and well tolerated in select patients with early-stage breast cancer, with no reported local recurrences and good to excellent cosmetic results. The pathologic response rates associated with this nonablative APBI dose regimen are particularly encouraging and support further exploration of this paradigm.
PURPOSE: To assess the feasibility of utilizing 3-dimensional conformal accelerated partial-breast irradiation (APBI) in the preoperative setting followed by standard breast-conserving therapy. PATIENTS AND METHODS: This was a prospective trial testing the feasibility of preoperative APBI followed by lumpectomy for patients with early-stage invasive ductal breast cancer. Eligible patients had T1-T2 (<3 cm), N0 tumors. Patients received 38.5 Gy in 3.85-Gy fractions delivered twice daily. Surgery was performed >21 days after radiation therapy. Adjuvant therapy was given as per standard of care. RESULTS: Twenty-seven patients completed treatment. With a median follow-up of 3.6 years (range, 0.5-5 years), there have been no local or regional failures. A complete pathologic response according to hematoxylin and eosin stains was seen in 4 patients (15%). There were 4 grade 3 seromas. Patient-reported cosmetic outcome was rated as good to excellent in 79% of patients after treatment. CONCLUSIONS: Preoperative 3-dimensional conformal radiation therapy-APBI is feasible and well tolerated in select patients with early-stage breast cancer, with no reported local recurrences and good to excellent cosmetic results. The pathologic response rates associated with this nonablative APBI dose regimen are particularly encouraging and support further exploration of this paradigm.
Authors: D Tiberi; P Vavassis; D Nguyen; M C Guilbert; A Simon-Cloutier; P Dubé; M K Gervais; L Sideris; G Leblanc; T Hijal; M P Dufresne; M Yassa Journal: Curr Oncol Date: 2020-06-01 Impact factor: 3.677
Authors: Brahma Natarajan; Daphna Spiegel; Elizabeth M Nichols; Steven Feigenberg; Rachel Blitzblau; Gloria Broadwater; Eileen A Duffy; Jay A Baker; Janet K Horton Journal: Int J Radiat Oncol Biol Phys Date: 2018-06-05 Impact factor: 7.038
Authors: James W Snider; Elizabeth M Nichols; Yildirim D Mutaf; Shifeng Chen; Jason Molitoris; Tejan Diwanji; Stewart J Becker; Steven J Feigenberg Journal: J Appl Clin Med Phys Date: 2021-03-03 Impact factor: 2.102
Authors: Ramona K Charaghvandi; Sua Yoo; Bram van Asselen; Anna Rodrigues; Desirée H J G van den Bongard; Janet K Horton Journal: Clin Transl Radiat Oncol Date: 2017-09-08
Authors: Matthew Mouawad; Heather Biernaski; Muriel Brackstone; Michael Lock; Brian Yaremko; Olga Shmuilovich; Anat Kornecki; Ilanit Ben Nachum; Giulio Muscedere; Kalan Lynn; Frank S Prato; R Terry Thompson; Stewart Gaede; Neil Gelman Journal: Clin Transl Radiat Oncol Date: 2019-12-25